Features and properties of bimatoprost implant

Alternative names	Bimatoprost SR; bimatoprost sustained-release implant; Durysta™
Class	Amides; antiglaucomas; lipids; prostaglandins; small molecules
Mechanism of action	Prostaglandin F2α receptor agonist
Route of administration	Implantation
Pharmacodynamics	Acts to lower intraocular pressure by increasing outflow of aqueous humour through both the trabecular meshwork (conventional) and uveoscleral routes (unconventional)
Pharmacokinetics	Following administration of bimatoprost implant, the highest concentrations of bimatoprost plus the metabolite bimatoprost acid are found in the iris–ciliary body (based on a study in dogs); minimal systemic exposure
Most common adverse reactions	Conjunctival hyperaemia, foreign body sensation, eye pain, photophobia, conjunctival haemorrhage, dry eye, eye irritation, intraocular pressure increased, corneal endothelial cell loss, vision blurred, iritis, headache
ATC codes:
WHO ATC code	S01E-E03 (Bimatoprost)
EphMRA ATC code	S1E (Miotics and Antiglaucoma Preparations)
Chemical name	(Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenyl-1-pentenyl]cyclopentyl]-N-ethyl-5-heptenamide